INDIVIDUAL ARTICLE: Evidence-Based Synthesis of Deucravacitinib: Long Term Efficacy, Safety, and Practical Use in Moderate-to-Severe Psoriasis
{{output}}
Background: Deucravacitinib, a first-in-class, oral, selective TYK2 inhibitor, has redefined systemic therapy options for moderate-to-severe plaque psoriasis. This review synthesizes published data from the POETYK phase 3 and lon... ...
